



Financial Tear Sheet

Corporate Profile

AVEO Oncology (AVEO) is a biopharmaceutical company dedicated to advancing a broad portfolio of targeted therapeutics for oncology and other areas of unmet medical need. The Company is focused on seeking to develop and commercialize its lead candidate tivozanib, a potent, selective, long half-life inhibitor of vascular endothelial growth factor 1, 2 and 3 receptors, in North America as a treatment for renal cell carcinoma. AVEO is leveraging multiple partnerships aimed at developing and commercializing tivozanib in oncology indications outside of North America, and progressing its pipeline of novel therapeutic candidates in cancer, cachexia (wasting syndrome) and Pulmonary Arterial Hypertension (PAH).

AVEO Oncology
Investor Relations
Phone: 617-588-1960
E-mail:
ir@aveooncology.com

Stock Performance

AVEO (COMMON STOCK)

Exchange	NASDAQ (US Dollar)
Price	\$2.82
Change (%)	▼ 0.02 (0.70%)
Volume	1,372,816
52 Week Low	\$0.50
Market Cap	\$333,666,238
Rolling EPS	-0.74
PE Ratio	N/A
Shares Outstanding	118,321,361

Data as of 01/17/18 4:00 p.m. ET



Recent Headlines

01/04/18
AVEO Oncology to Present at the 36th Annual J.P. Morgan Healthcare Conference

01/02/18
AVEO Oncology Announces Refinanced Debt Facility

12/07/17
AVEO Oncology Announces Clinical Updates to Tivozanib and Ficlatusumab Programs

Events

There are currently no events scheduled.

SEC Filings

FILING DATE FORM

01/04/18	8-K
01/02/18	8-K
12/26/17	8-K
12/15/17	EFFECT

Powered By **EDGAR**Online

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Minimum 20 minutes delayed